Treatment of anxiety disorders with venlafaxine XR

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Expert Review of Neurotherapeutics

• Publication date

  2006-03-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1586/14737175.6.3.269PMID 16533131
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder

  2012cited by this paper
• Monoamine Oxidase Inhibitors and Serotonin Syndrome

  2007cited by this paper
• Discontinuation symptoms in depression and anxiety disorders.

  2007cited by this paper
• Social Anxiety Disorder

  2005cited by this paper
• Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.

  2005cited by this paper
• A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder.

  2005cited by this paper
• Effects of the Committee on Safety of Medicines Advice on Antidepressant Prescribing to Children and Adolescents in the UK

  2005cited by this paper
• Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study.

  2005cited by this paper
• Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.

  2005cited by this paper
• Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication.

  2005cited by this paper
• Fluoxetine versus other types of pharmacotherapy for depression.

  2005cited by this paper
• Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram

  2005cited by this paper
• Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

  2005cited by this paper
• A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK

  2005cited by this paper
• Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom

  2005cited by this paper
• Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data

  2004cited by this paper
• Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study

  2004cited by this paper
• Venlafaxine versus placebo in the preventive treatment of recurrent major depression.

  2004cited by this paper
• P.3.006 A double-blind, placebo-controlled trial ofvenlafaxine XR in the short-term treatment of panic disorder

  2004cited by this paper
• Psychotherapy alone and combined with pharmacotherapy in the treatment of depression

  2004cited by this paper
• Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial

  2004cited by this paper
• Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder.

  2004cited by this paper
• P.3.007 Safety and efficacy of venlafaxine ER in the treatment of pediatric social anxiety disorder

  2004cited by this paper
• Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double‐blind, placebo‐controlled, parallel‐group comparison with paroxetine

  2004cited by this paper
• Current Use of Selective Serotonin Reuptake Inhibitors and Risk of Acute Myocardial Infarction

  2004cited by this paper
• Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.

  2004cited by this paper
• A Double-Blind, Placebo-Controlled Study of a Flexible Dose of Venlafaxine ER in Adult Outpatients With Generalized Social Anxiety Disorder

  2004cited by this paper
• Cost-Effectiveness of Psychological and Pharmacological Interventions for Generalized Anxiety Disorder and Panic Disorder

  2004cited by this paper
• What is a "mood stabilizer"? An evidence-based response.

  2004cited by this paper
• A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder.

  2004cited by this paper
• Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

  2004cited by this paper
• Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants.

  2003cited by this paper
• A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care.

  2003cited by this paper
• P.3.062 Venlafaxine XR and sertraline in PTSD: A placebo-controlled study

  2003cited by this paper
• A Double Blind Comparison of Venlafaxine and Paroxetine in Obsessive-Compulsive Disorder

  2003cited by this paper
• P.3.056 Pregabalin in generalized anxiety disorder: Influence of subsyndromic depression

  2003cited by this paper
• P.3.058 Venlafaxine XR and paroxetine in the short-term treatment of panic disorder

  2003cited by this paper
• Moclobemide: therapeutic use and clinical studies.

  2003cited by this paper
• Predictors of Outcome Following Venlafaxine Extended-Release Treatment of DSM-IV Generalized Anxiety Disorder: A Pooled Analysis of Short- and Long-Term Studies

  2003cited by this paper
• A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder

  2003cited by this paper
• Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity.

  2003cited by this paper
• Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis.

  2002cited by this paper
• Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety.

  2002cited by this paper
• Antidepressant Side Effects in Depression Patients Treated in a Naturalistic Setting: A Study of Bupropion, Moclobemide, Paroxetine, Sertraline, and Venlafaxine

  2002cited by this paper
• Comparing the methods used to compare antidepressants.

  2002cited by this paper
• Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms

  2002cited by this paper
• Effectiveness of Venlafaxine, Extended Release Formulation, in the Short-Term and Long-Term Treatment of Generalized Anxiety Disorder: Results of a Survival Analysis

  2002cited by this paper
• Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study.

  2002cited by this paper
• A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers.

  2002cited by this paper
• Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups.

  2002cited by this paper
• Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR.

  2002cited by this paper
• Prevalence of sexual dysfunction among newer antidepressants.

  2002cited by this paper
• The next step forward: a move toward evidence, and away from fear of the industry.

  2002cited by this paper
• Review of sertraline in post-traumatic stress disorder

  2002cited by this paper
• Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data

  2002cited by this paper
• Venlafaxine ER as a Treatment for Generalized Anxiety Disorder in Older Adults: Pooled Analysis of Five Randomized Placebo‐Controlled Clinical Trials

  2002cited by this paper
• Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa Depression Study.

  2002cited by this paper
• Improvement in functionality with treatment of generalized social anxiety disorder: Venlafaxine XR vs placebo

  2002cited by this paper
• Venlafaxine Extended Release (ER) in the Treatment of Generalised Anxiety Disorder

  2001cited by this paper
• Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.

  2001cited by this paper
• Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

  2001cited by this paper
• Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.

  2001cited by this paper
• Pharmacotherapy of generalized anxiety disorder.

  2001cited by this paper
• Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers.

  2001cited by this paper
• Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety.

  2001cited by this paper
• Patient perspectives on once-weekly fluoxetine.

  2001cited by this paper
• Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat.

  2000cited by this paper
• Efficacy of venlafaxine in mixed depression‐anxiety states

  2000cited by this paper
• Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: Focus on venlafaxine

  2000cited by this paper
• Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

  2000cited by this paper
• Neuropharmacology of venlafaxine

  2000cited by this paper
• Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine.

  2000cited by this paper
• Evidence of the dual mechanisms of action of venlafaxine.

  2000cited by this paper
• Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

  2000cited by this paper
• Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.

  1999cited by this paper
• Newer antidepressants: a comparison of tolerability in general practice.

  1999cited by this paper
• Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein.

  1999cited by this paper
• The economic burden of anxiety disorders in the 1990s.

  1999cited by this paper
• Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man

  1999cited by this paper
• Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.

  1999cited by this paper
• A meta-analysis of the effects of venlafaxine on anxiety associated with depression.

  1998cited by this paper
• Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action.

  1998cited by this paper
• ECT, research, and professional ambivalence.

  1998cited by this paper
• Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety.

  1998cited by this paper
• Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients.

  1998cited by this paper
• Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients.

  1998cited by this paper
• Venlafaxine, monoamine oxidase inhibitors, and the serotonin syndrome.

  1997cited by this paper
• Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.

  1997cited by this paper
• A Risk-Benefit Assessment of Buspirone in the Treatment of Anxiety Disorders

  1997cited by this paper
• Economic costs of anxiety disorders.

  1996cited by this paper
• Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study.

  1996cited by this paper
• Cardiovascular safety in depressed patients: focus on venlafaxine.

  1995cited by this paper
• Cardiovascular safety in depressed patients: focus on venlafaxine.

  1995cited by this paper
• Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.

  1994cited by this paper
• Rapid down regulation of beta-adrenoceptors by co-administration of desipramine and fluoxetine.

  1988cited by this paper
• Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative.

  1986cited by this paper
• Lifetime prevalence of specific psychiatric disorders in three sites.

  1984cited by this paper
• Controlled double-blind trail of flavoxate in painful conditions of the lower urinary tract.

  1974cited by this paper

• Venlafaxine Upregulates Cortical Catechol-O-methyltransferase Expression and Activity in Rats and Mice

  2026cites this paper
• Genetic Guidance in Personal Neurological Treatment. Mini Review

  2023cites this paper
• The Rat in Neuroscience Research

  2020cites this paper
• Association between serotonin-norepinephrine reuptake inhibitors and acute angle closure: What is known?

  2019cites this paper
• Antidepressant mechanisms of venlafaxine involving increasing histone acetylation and modulating tyrosine hydroxylase and tryptophan hydroxylase expression in hippocampus of depressive rats

  2019cites this paper
• Inhibition of the G9a/GLP histone methyltransferase complex modulates anxiety-related behavior in mice

  2018cites this paper
• The effect of paroxetine, venlafaxine and bupropion administration alone and combined on spatial and aversive memory performance in rats

  2018cites this paper
• Assessing the effects of the antidepressant venlafaxine to fathead minnows exposed to environmentally relevant concentrations over a full life cycle.

  2017cites this paper
• Study of Anxiolytic Activity in Mice Using Vacha Churnam (Rasayana Preparation- Ayurvedic System of Medicine)

  2017cites this paper
• ROLE OF DIFFERENT NEUROTRANSMITTERS IN ANXIETY: A SYSTEMIC REVIEW

  2017cites this paper
• Chapter 7 – Antidepressants

  2016cites this paper
• Pharmacological Inhibition of the G9a/GLP Histone Methyltransferase and Anxiety-related Behaviour in the Mouse

  2016cites this paper
• Influencia de la administración de psicofármacos en el aumento del peso corporal

  2013cites this paper
• Emprego clínico, uso indevido e abuso de benzodiazepínicos: uma revisão

  2012cites this paper
• Venlafaxine facilitates between-session extinction and prevents reinstatement of auditory-cue conditioned fear.

  2012cites this paper
• Pharmacotherapy for Generalized Anxiety Disorder

  2011cites this paper
• Venlafaxine and Desvenlafaxine, Selective Norepinephrine and Serotonin Reuptake Inhibitors to Treat Major Depressive Disorder

  2010cites this paper
• An Integrated Model of Panic Disorder

  2010cites this paper
• Pharmacotherapy of PTSD: premises, principles, and priorities.

  2009cites this paper
• Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial

  2009cites this paper
• Current Considerations in the Treatment of Generalized Anxiety Disorder

  2009cites this paper
• Change in Pain Severity With Open Label Venlafaxine Use in Patients With a Depressive Symptomatology: An Observational Study in Primary Care

  2008cites this paper
• [Agoraphobia: combined treatment and virtual reality. Preliminary results].

  2008cites this paper
• P0080 - Efficacy of Pregabalin and Venlafaxine-XR in generalized anxiety disorder: Results of a double-blind, placebo-controlled 8-week trial

  2008influential citation
• Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder

  2008cites this paper
• Desvenlafaxine succinate for the treatment of major depressive disorder

  2008cites this paper
• Agorafobia: tratamientos combinados y realidad virtual. Datos preliminares

  2008cites this paper
• Cambio en la intensidad del dolor con venlafaxina administrada de forma abierta en pacientes con sintomatología depresiva: estudio de observación en la atención primaria

  2008cites this paper
• [Early detection and treatment of panic disorder with or without agoraphobia: update].

  2007cites this paper
• Regulation of anxiety during the postpartum period.

  2007cites this paper
• Chapter 2 Recent Developments in Monoamine Reuptake Inhibitors

  2007cites this paper
• The 5-HT1A Receptor: A Signaling Hub Linked to Emotional Balance

  2007cites this paper
• Painful physical symptoms in depression: a clinical challenge.

  2007cites this paper
• L’identification et traitement du trouble panique avec ou sans agoraphobie: Mise à jour

  2007cites this paper
• Management of psychiatric comorbidity in fibromyalgia

  2006cites this paper